Skip to Content
Merck
All Photos(1)

Key Documents

T2005000

Triflusal

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid

Sign Into View Organizational & Contract Pricing

Select a Size

50 MG
$204.00

$204.00

Estimated to ship on12 April 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
50 MG
$204.00

About This Item

Empirical Formula (Hill Notation):
C10H7F3O4
CAS Number:
322-79-2
Molecular Weight:
248.16
UNSPSC Code:
41116107
NACRES:
NA.24

$204.00

Estimated to ship on12 April 2025

Request a Bulk Order

grade

pharmaceutical primary standard

API family

triflusal

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C

InChI

1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)

InChI key

RMWVZGDJPAKBDE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Triflusal EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H317,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David Murdoch et al.
Drugs, 66(5), 671-692 (2006-04-20)
Triflusal (Aflen, Disgren, Tecnosal, Triflux) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk
José Antonio González-Correa et al.
Cardiovascular drug reviews, 24(1), 11-24 (2006-08-31)
Triflusal is a derivative of salicylic acid with a well-established platelet aggregation inhibitory profile. Its pharmacokinetic and pharmacodynamic properties differ, however, somewhat from those of acetylsalicylic acid. A number of recent experimental and clinical studies have shown that triflusal is
Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness.
Hector Anninos et al.
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, 50(3), 199-207 (2009-05-26)
J Alvarez Sabín et al.
Revista de neurologia, 27(160), 951-955 (1999-02-10)
Different studies have shown that aspirin (AAS), in low doses, may lead to a considerable frequency of hemorrhagic complications when used in the long term. We compare the long-term occurrence of hemorrhagic complications with low doses of AAS and high
J Costa et al.
The Cochrane database of systematic reviews, (3)(3), CD004296-CD004296 (2005-07-22)
Aspirin is the standard treatment for secondary prevention of stroke and other vascular events. Several studies suggest that triflusal may have a better safety profile. To determine in people at high risk of vascular events whether triflusal is an effective
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service